Harvard Apparatus Regenerative Technology, Inc.

Overview

Compare with Co-Diagnostics, Inc., Flyte Aviation, Inc. or Aethlon Medical, or pick any stock.

• TickerHRGN on OTC¹
• IndustrySurgical & Medical Instruments & Apparatus¹
• HeadquartersHolliston, Massachusetts¹
• Incorporated inDE²
• Business address84 October Hill Road, Suite 11, Holliston, Ma 01746²
• Filer categoryNon-accelerated filer, Smaller reporting company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastro-intestinal system and other organs that result from cancer, trauma or birth defects. Our technology is based on our proprietary cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. We believe that our technology represents a next generation solution for restoring organ function because it allows the patient to regenerate their own organ, thus eliminating the need for human donor or animal transplants, the sacrificing of another of the patient’s own organs or permanent artificial implants.³ From its latest annual report

Corporate structure

Harvard Apparatus Regenerative Technology, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Harvard Apparatus Regenerative Technology, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Inventory

Properties, in its own words

On August 12, 2024, the Company entered into an operating lease agreement for approximately 10,629 square feet of office, research and development and light manufacturing space located in located at 84 October Hill Road, Suite 11, Holliston, Massachusetts. The term of the lease ends on August 31, 2027. The space will continue to serve as the Company’s corporate headquarters and incorporate manufacturing, laboratory, development, sales and marketing, and administration functions. We believe our current facilities are adequate for our needs for the foreseeable future.

Item 2 of the 10-K filed Mar 19, 2026.³

Leadership

Who has led Harvard Apparatus Regenerative Technology, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerJunli He Apr 12, 2023 to now¹²
• Chief executive officerThomas McNaughton Jun 1, 2015 to Jun 3, 2015¹³
• Chief executive officerJames Joseph McGorry Jul 7, 2015 to Jun 14, 2018¹⁴
• PresidentFrancesca Saverio La Aug 24, 2017 to Aug 25, 2017¹⁵
• PresidentJames Joseph McGorry Jul 7, 2015 to Aug 25, 2016¹⁴
• Chief financial officerJoseph Luis Damasio Jr. Aug 9, 2022 to Aug 9, 2022¹⁶
• Chief financial officerThomas McNaughton Oct 21, 2013 to Jun 18, 2019¹⁷

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerHong Yu named Jun 8, 2022 to Sep 14, 2026³⁵
• Executive OfficerShunfu Hu named Jun 8, 2022 to Sep 14, 2026³⁵
• DirectorDavid Green named Jun 8, 2022 to Sep 14, 2026³⁵
• DirectorJing Chen named Jun 8, 2022 to Sep 14, 2026³⁵
• DirectorMao Zhang named Jul 14, 2025 to Sep 14, 2026³⁵

Former names

• Biostage, Inc.Apr 5, 2016 to Jul 10, 2023²

Timeline

1. Sep 14, 20268-K Entered a material agreement; Unregistered sale of shares³⁶
2. Aug 3, 20268-K Entered a material agreement; New debt or obligation³⁷
3. Aug 3, 20268-K Entered a material agreement; New debt or obligation³⁸
4. Jun 24, 20268-K Shareholder vote³⁹
5. Apr 28, 20268-K Regulation FD disclosure⁴⁰
6. Apr 15, 20268-K Ended a material agreement⁴¹
7. Jan 6, 20268-K Entered a material agreement; Unregistered sale of shares⁴²
8. Jul 14, 20258-K Entered a material agreement; Unregistered sale of shares⁴³
9. Jun 24, 20258-K Shareholder vote⁴⁴
10. Apr 14, 20258-K Change of auditor⁴⁵
11. Nov 6, 20248-K Entered a material agreement⁴⁶
12. Aug 27, 20248-K Executive or director change⁴⁷
13. Apr 12, 2023New chief executive Junli He becomes CEO¹²
14. Jul 7, 2015New chief executive James Joseph McGorry becomes CEO¹⁴
15. Jun 1, 2015New chief executive Thomas McNaughton becomes CEO¹³

Calendar

When it reported results

1. Nov 14, 2022Reported quarterly or annual results⁴⁸
2. Aug 4, 2022Reported quarterly or annual results⁴⁹
3. May 16, 2022Reported quarterly or annual results⁵⁰
4. Apr 1, 2022Reported quarterly or annual results⁵¹
5. Nov 15, 2021Reported quarterly or annual results⁵²

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

164 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 44 major events, 72 insider forms, 5 large holders, 6 private raises, 17 other. The latest 20:

1. Sep 25, 20264 EDGAR
2. Sep 14, 20268-K EDGAR
3. Sep 14, 2026D EDGAR
4. Aug 13, 202610-Q EDGAR
5. Aug 11, 20264 EDGAR
6. Aug 3, 20268-K EDGAR
7. Aug 3, 20268-K/A EDGAR
8. Jun 24, 20268-K EDGAR
9. May 13, 202610-Q EDGAR
10. Apr 28, 20268-K EDGAR
11. Apr 23, 2026DEF 14A EDGAR
12. Apr 15, 20268-K EDGAR
13. Mar 19, 202610-K EDGAR
14. Jan 6, 2026D EDGAR
15. Jan 6, 20268-K EDGAR
16. Dec 1, 20254 EDGAR
17. Nov 7, 202510-Q EDGAR
18. Oct 1, 20254 EDGAR
19. Sep 24, 20254 EDGAR
20. Sep 2, 20254 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

25 open-market trades by officers, directors and large owners since October 2021: 21 buys and 4 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• STELLARS CAPITAL PRIVATE I LtdSC 13D, 1 filing Sep 26, 2024⁵³
• DST Capital LLCSC 13D/A, 1 filing Aug 16, 2024⁵⁴
• An ZhangSC 13G/A, 1 filing Feb 16, 2023⁵⁵

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Money raised

Private offerings the company reported to the SEC on Form D.

1. Sep 11, 2026Raised $2.8 million in a private offering of equity Form D: $3 million offered in all Form D
2. Dec 30, 2025Raised $700,000 in a private offering of equity Form D: $2 million offered in all Form D
3. Jul 11, 2025Raised $2 million in a private offering of equity Form D: 2 investors so far Form D
4. Apr 15, 2024Raised $1.5 million in a private offering of equity Form D: 4 investors so far Form D
5. Mar 31, 2023Raised $6 million in a private offering of equity Form D: 14 investors so far Form D
6. May 12, 2022Raised $5.1 million in a private offering of equity Form D: 25 investors so far Form D

SEC filer profile

How Harvard Apparatus Regenerative Technology, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARHarvard Apparatus Regenerative Technology, Inc.¹
• CIK0001563665
• Employer ID (EIN)45-5210462³
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company³
• Incorporated inDelaware³
• Fiscal year endsDecember 31¹
• Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address84 October Hill Road, Suite 11, Holliston, MA 01746¹
• Phone(774) 233-7300¹
• Shares outstanding17,580,744 as of Aug 10, 2026¹¹
• Public float$15.6M as of Jun 30, 2025³
• AuditorCBIZ CPAs P.C., Boston, MA PCAOB ID 199; no auditor attestation of internal control over financial reporting³
• On EDGAR sinceDec 11, 2012¹
• Filings625 in all: 4 (196), 8-K (168), 10-Q (39), 3 (33), D (15), DEF 14A (14), SC 13D/A (14), 10-K (13)¹
  All 43 form types

  CORRESP (11), SC 13G (11), SC 13G/A (10), DEFA14A (9), UPLOAD (9), S-1/A (8), S-8 (8), SC 13D (7), EFFECT (6), 4/A (5), PRE 14A (5), S-1 (5), 424B3 (3), 424B5 (3), 8-K/A (3), CERTNAS (3), POS AM (3), RW (3), 10-12B/A (2), 8-A12B (2), NT 10-Q (2), S-3 (2), 10-12B (1), 10-K/A (1), 25-NSE (1), 3/A (1), 424B4 (1), ARS (1), CT ORDER (1), D/A (1), DEFR14A (1), DEL AM (1), NT 10-K (1), POS EX (1), PRER14A (1)

• Latest filingsAnnual report (10-K) Mar 19, 2026
  Quarterly report (10-Q) Aug 13, 2026
  Proxy statement (DEF 14A) Apr 23, 2026
  Latest 8-K (8-K) Sep 14, 2026

Risk factors and legal proceedings

The risks Harvard Apparatus Regenerative Technology, Inc. names in Item 1A of its 10-K filed Mar 19, 2026: 50 risks under these headings, as written.³

• Risks Relating to Our Financial Position, Need for Capital and Operating Risks
• Our independent registered public accounting firm’s report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a “going concern.” Our audited financial statements for the year ended December 31, 2025 contain a going concern qualification. Our financial status creates doubt whether we will continue as a going concern. We will need additional funds in the near future and our operations will be adversely affected if we are unable to obtain needed funding.
• Our product candidates are in an early stage of development. If we are unable to develop or market any of our product candidates, our financial condition will be negatively affected, and we may have to curtail or cease our operations.
• We have generated insignificant revenue to date and have an accumulated deficit. We anticipate that we will incur losses for the foreseeable future. We may never achieve or sustain profitability.
• We have a limited operating history and it is difficult to predict our future growth and operating results.
• If we fail to retain key personnel and/or attract satisfactory replacements, we may not be able to compete effectively, which would have an adverse effect on our operations.
• If our collaborators do not devote sufficient time and resources to successfully carry out their duties or meet expected deadlines, we may not be able to advance our product candidates in a timely manner or at all.
• Public perception of ethical and social issues surrounding the use of cell technology may limit or discourage the use of our technologies, which may reduce the demand for our products and technologies and reduce our revenues.
• Our products will subject us to liability exposure.
• If restrictions on reimbursements or other conditions imposed by payers limit our customers’ actual or potential financial returns on our products, our customers may not purchase our products or may reduce their purchases.
• We depend upon single-source suppliers for the hardware used for our proprietary automatic cell seeder, bioreactor control and acquisition system. The loss of a single source supplier, or future single-source suppliers we may rely on, or their failure to provide us with an adequate supply of their products or services on a timely basis, could adversely affect our business.
• We use and generate hazardous materials in our business and must comply with environmental laws and regulations, which can be expensive.

Legal proceedings

From time to time, we may be involved in various claims and legal proceedings arising in the ordinary course of business. There are no such matters pending that we expect to be material in relation to our business, financial condition, and results of operations or cash flows.

The opening of Item 3, Legal Proceedings.³